Bronchodilator Drugs - LATAM

LATAM

Revenue in the Bronchodilator Drugs market is projected to reach US$1.20bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 3.74%, resulting in a market volume of US$1.39bn by 2028.
In global comparison, most revenue will be generated in the United States (US$17,340.00m in 2024).

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Bronchodilator Drugs market includes a rather high share of generics and OTC drugs which are relatively low-priced compared to drugs in other markets. On the other hand, the number of patients is higher for bronchodilators than for most more expensive drugs. With fewer patients seeking treatment because of the COVID-19 pandemic, the market size slightly decreased in 2020. For the coming years, moderate growth is expected.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.